The study is potentially a “leap forward” in cancer genomics, particularly for subsets of patients with metastatic and anaplastic thyroid cancer.
Treatment with the second-generation EGFR TKI dacomitinib resulted in improved overall survival over gefitinib in patients with NSCLC and activating EGFR mutations.
In the Utah Cancer Survivors Study, male thyroid cancer survivors had an almost 50% higher risk of developing cardiovascular disease than females.
A multicenter, international phase II study found higher-dose and extended-dose therapy with Ra-223 did not improve survival or pain scores.
The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.
In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care.
Overall response was strong even in high-risk patients (over age 65, with 17p deletion, with prior ibrutinib therapy, and mutations of BTK and PLCγ2).
FDA warns, however, about the possibility of TLS due to rapid tumor cell destruction.
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.